ClinGen Panel Validates 34 Glomerular Disease Genes for Clinical Use

Clarifying Genetic Links in Glomerular Disease

Genetic factors are a known contributor to many glomerular pathologies, yet the proliferation of genomic sequencing has presented clinicians with a significant interpretive challenge [1, 2, 3]. Distinguishing a truly pathogenic variant from benign ones is often difficult, creating uncertainty in how to apply genetic test results to patient care [4, 5]. Without a standardized method for evaluating the evidence linking a gene to a disease, clinicians risk misdiagnosis or basing management decisions on weak associations [6]. A recent consensus statement from a panel of experts now provides a systematic framework for assessing the clinical validity of genes implicated in glomerular disease, offering needed clarity for diagnostic testing [7].

The Imperative of Gene Curation in Nephrology

While many glomerular diseases have a genetic component, the presence of a genetic variant does not automatically confirm pathogenicity. To address this ambiguity, the field relies on a formal process known as gene curation. This is the systematic evaluation of all available genetic and experimental evidence to rigorously determine the validity of a purported gene-disease relationship. The goal of gene curation is to provide an evidence-based standard, enabling clinicians to distinguish genes with a strong causal link to a disease from those with only a speculative or unproven association. This process is essential for deciding which genes warrant inclusion on diagnostic testing panels and which can reliably guide clinical management.

This critical task is a primary function of the Clinical Genome Resource (ClinGen), an NIH-funded consortium. ClinGen convenes genetic and disease-specific expert panels to conduct comprehensive reviews and produce standardized, transparent assessments of gene-disease relationships. By establishing which associations are robust, ClinGen's work provides a foundational resource for the practice of precision medicine, giving clinicians a greater degree of confidence when interpreting genetic reports and making patient care decisions.

Expert Consensus on Glomerular Gene Validity

The ClinGen Glomerulopathy Gene Curation Expert Panel has completed its initial comprehensive evaluation of genes associated with glomerular phenotypes. The panel systematically reviewed the evidence for 57 distinct gene-disease relationships involving 56 different genes. The objective was to categorize each association based on the strength of the supporting evidence, thereby creating a validated list for clinical use.

The panel's findings provide a clear hierarchy of clinical validity. Of the genes reviewed, 34 were found to have a definitive level of evidence supporting their role in glomerular disease. This classification signifies a strong, well-supported causal link, making these genes appropriate targets for diagnostic testing. In addition, ten genes were classified as having moderate supporting evidence and eleven had limited supporting evidence, suggesting that while an association may exist, more data are needed before they can be used for routine clinical decision-making. Finally, two genes were determined to have insufficient evidence to support any clinically valid relationship to glomerular disease, highlighting the importance of this rigorous vetting process.

Clinical Implications for Diagnostic Testing and Management

The findings from the ClinGen Glomerulopathy Gene Curation Expert Panel have direct applications for practicing physicians. The establishment of 34 genes with definitive clinical validity for causing glomerular disease provides an evidence-based foundation for the design and interpretation of genetic testing panels. Clinicians ordering such tests can now better gauge the relevance of the genes included and have greater confidence in the results. This curation offers a valuable reference that helps separate high-utility diagnostic targets from genes with weaker or unsubstantiated links to disease.

This framework allows for more precise clinical action. A positive finding for a gene with definitive evidence can inform prognostication, guide considerations for specific therapies, and facilitate accurate genetic counseling for patients and their families. Conversely, when a variant is identified in a gene with only moderate or limited evidence, this classification encourages appropriate clinical caution. It signals that the genetic finding, while potentially relevant, should not be the sole basis for major management decisions without further corroborating evidence. This tiered system ultimately helps clinicians translate complex genetic data into more reliable and responsible patient care.

References

1. Major R, Cheng MRI, Grant RA, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS ONE. 2018. doi:10.1371/journal.pone.0192895

2. Groopman E, Marasà M, Cameron‐Christie S, et al. Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine. 2018. doi:10.1056/nejmoa1806891

3. Whiffin N, Armean IM, Kleinman A, et al. The effect of LRRK2 loss-of-function variants in humans. Nature Medicine. 2020. doi:10.1038/s41591-020-0893-5

4. Collin CB, Gebhardt T, Golebiewski M, et al. Computational Models for Clinical Applications in Personalized Medicine—Guidelines and Recommendations for Data Integration and Model Validation. Journal of Personalized Medicine. 2022. doi:10.3390/jpm12020166

5. Krueger DA, Northrup H, Northrup H, et al. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology. 2013. doi:10.1016/j.pediatrneurol.2013.08.002

6. Yu K, Healey E, Leong T, Kohane IS, Manrai AK. Medical Artificial Intelligence and Human Values. New England Journal of Medicine. 2024. doi:10.1056/nejmra2214183

7. Byrne AB, Li AS, Chung EYM, et al. Gene-disease relationships for glomerular phenotypes: expert recommendations from ClinGen.. Nature reviews. Nephrology. 2026. doi:10.1038/s41581-026-01087-9